Furthermore, CDK12 mutations in melanoma are already known to impact immunotherapy response [61] Analysis of Reduced CDK12/13 expression in metastatic melanoma patients significantly predicted improved survival and response to immune checkpoint blockade [61]. Here, CDK12 is linked to melanoma.